610 / 1498
Conclusions therapy in advanced stage FL
• Decision-making to treat in the frontline therapy based on; disease
burden, patient symptoms, patient characteristics, morbidities and
patient choice
• Right choice of initial therapy is the one that gives the best chance
of durable remission and lowest toxicity profile for that patient.
• R-Chemo standard of care, randomised studies versus
Lenalidomide and Rituximab awaited
• Maintenance Rituximab in responders to induction R-Chemo
chemotherapy plus rituximab
• Novel drugs including PI3Kδ inhibition appear effective in relapsed
and refractory FL